Clavulanate Potassium with Silicon Dioxide (Syloid)
.
 
 
Characteristics:
A blended powder mixture of Clavulanate potassium and silicon dioxide
Weight Ratio 1:1

Application:
The product is suitable for the manufacture of powder for deferral following the accumulation of proper Excipients and Amoxicillin.

Therapeutic category:
 A beta- lactamase inhibitor that augments the activity of amoxicillin as a wide-ranging antibiotic

Pharmacopoeia Quality:
The Clavulanate potassium conforms to the
- USP
- Ph.Eur.
- BP
latest editions

Appearance:
White to off-white crystalline powder

Content (HPLC):
K-Clavulanate: 46.1 - 52.8%
(clavulanic acid): (38.7 - 44. 3%)

Water (Karl Fischer): < 1.5 %

Tapped bulk density (U SP): > 0.25 g/ml

Shelf life:
3 years in the original packaging beneath 'storage conditions

Storage conditions:
 Less than 15 °C, protected from light and moisture

Packaging:
See segment "Packaging"

Regulatory Information:
See segment "Regulatory Information"
 
The information contained herein is believed to be accurate but all recommendations are made without warranty and nothing be construed to imply any guarantee.
 
Pharma categories patient's education business prospect feedback
     
Sitemap Our Import Products  
Home
Profile
Products List
Import List
Services
Marketing
Quality Control
Feedback
Contact
Disclaimer
Sitemap
Amino Acids
Cefuroxime sodium sterile
Clavulanate Potassium with Amoxycillin
Clavulanate Potassium with microcrystalline cellulose
Clavulanate Potassium with Silicon Dioxide (Syloid)
Citicoline
Follicle Stimulating Hormone (FSH)
Human Chorionic Gonadotropin (HCG)
Human Menotropin Gonadotropin ( HMG)
Hydrocortisone Sodium Succinate
Imipenem And Cilastatin USP
Methyl Prednisolone Sodium succinate
Methyl Prednisolone Acetate
Methyl Prednisolone Base
Mifepristone BP
Misoprostol HPMC 1% Dispersion powder
(UK PIRAMAL - exclusive agent in india)
Orlistat
Progesterone BP
Spiramycin
Teicoplanin
Tranexamic Acid BP